Rubius Therapeutics to Announce Second Quarter 2020 Financial Results
August 03 2020 - 4:01PM
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage
biopharmaceutical company that is genetically engineering red blood
cells to create an entirely new class of cellular medicines, today
announced plans to report second quarter 2020 financial results
on Monday, August 10, 2020, before market open.
The company will not be conducting a teleconference in
conjunction with its financial results press release.
About Rubius Therapeutics Rubius
Therapeutics, Inc. (Nasdaq:RUBY) is a clinical-stage
biopharmaceutical company that is genetically engineering red blood
cells to create an entirely new class of cellular medicines called
Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM®
genetically engineers and cultures Red Cell Therapeutics to create
selective, potent and off-the-shelf allogeneic cellular therapies
for the potential treatment of cancer and autoimmune diseases.
Rubius’ initial product candidates are designed to activate and
expand immune system function to fight cancer and modulate the
immune system to induce tolerance for the treatment of autoimmune
diseases. For more information, visit www.rubiustx.com, follow us
on Twitter or LinkedIn or like us on Facebook.
Contacts:Lori Melançon Vice President,
Corporate Communications and Investor Relations +1 (617)
949-5296lori.melancon@rubiustx.com
Media: Marissa HanifyDirector, Corporate
Communicationsmarissa.hanify@rubiustx.com
Dan Budwick 1AB +1 (973)
271-6085dan@1abmedia.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jul 2023 to Jul 2024